Clinicopathologic and Molecular Profiles of Microsatellite Unstable Barrett Esophagus-associated Adenocarcinoma by Farris, Alton B. et al.
 
Clinicopathologic and Molecular Profiles of Microsatellite
Unstable Barrett Esophagus-associated Adenocarcinoma
 
 
(Article begins on next page)
The Harvard community has made this article openly
available.
Please share how this access benefits you. Your story
matters.
Citation Farris, Alton B., Elizabeth G. Demicco, Long Phe Le, Karin E.
Finberg, Julie Miller, Rajni Mandal, Junya Fukuoka, et al.
2011. Clinicopathologic and molecular profiles of
microsatellite unstable Barrett esophagus-associated
adenocarcinoma. The American Journal of Surgical Pathology
35(5): 647–655.
Published Version doi:10.1097/PAS.0b013e31820f18a2
Accessed February 16, 2015 10:09:06 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12490654
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and
conditions applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAClinicopathologic and Molecular Profiles of Microsatellite
Unstable Barrett Esophagus-associated Adenocarcinoma
Alton B. Farris, III, MD,*w Elizabeth G. Demicco, MD, PhD,* Long Phe Le, MD, PhD,*
Karin E. Finberg, MD, PhD,*z Julie Miller, BS,* Rajni Mandal, MD,* Junya Fukuoka, MD,y
Cynthia Cohen, MD,w Henning A. Gaissert, MD,J Lawrence R. Zukerberg, MD,*
Gregory Y. Lauwers, MD,* A. John Iafrate, MD, PhD,* and Mari Mino-Kenudson, MD*
Abstract: Microsatellite instability (MSI) has been reported in
various tumors, with colon cancer as the prototype. However, little
is known about MSI in Barrett esophagus (BE)-associated
adenocarcinoma. Thus, the aim of this study was to compare the
clinicopathologic and molecular features of BE-associated adeno-
carcinomas with and without MSI. The study cohort consisted of
76 patients with BE-associated adenocarcinomas (66 male, 10
female), with a mean age of 65.1 years. Immunohistochemistry
(IHC) for MLH1, MSH2, MSH6, PMS2, and CD3 and in situ
hybridization for Epstein-Barr virus-encoded RNA were per-
formed. MLH1 and PMS2 expression was lost by IHC in 5 cases
(6.6%); of these, 5 showed high-level MSI (MSI-H) by polymerase
chain reaction assay, and 4 showed hMLH1 promoter methyla-
tion. Histologically, tumors with MSI-H were heterogenous and
included conventional adenocarcinomas with tumor-inﬁltrating
lymphocytes (n=1), medullary carcinoma (n=2), signet ring cells
(n=1), and signet ring cell and mucinous components (n=1).
Compared with tumors negative for MSI by IHC, BE-associated
adenocarcinomas with MSI-H were associated with older patient
age (P=0.0060), lymphovascular invasion (P=0.027), and
signiﬁcantly larger numbers of tumor-inﬁltrating lymphocytes
(P<0.0001). However, there was no statistical diﬀerence in overall
survival between the 2 groups (P=0.285). In conclusion, MSI-H is
uncommon in BE-associated adenocarcinomas, but is associated
with clinicopathologic features fairly similar to sporadic micro-
satellite unstable colorectal cancers. Given the growing evidence
that indicates lack of beneﬁts from adjuvant therapy with
ﬂuorouracil in the colonic counterpart, it may be important to
identify MSI-H in BE-associated adenocarcinomas.
Key Words: Barrett esophagus, esophageal adenocarcinoma,
microsatellite instability, histology, medullary carcinoma, tumor-
inﬁltrating lymphocyte
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E
sophageal cancer is a neoplasm with a poor prognosis
that has attracted more attention in recent years. In
2010, it was predicted that well over 16,000 new cases of
esophageal cancer would be diagnosed with an estimated
death toll of approximately 14,500 patients.2 Since the
mid-1970s, the incidence of esophageal adenocarcinoma
has risen >350% among white men and has surpassed
the incidence of squamous cell carcinoma.11 Overall,
esophageal adenocarcinoma has a poor prognosis, with
<50% of patients surviving 1 year after diagnosis.11 Over
the last 2 decades, multiple epidemiologic studies on the
etiology of esophageal adenocarcinoma have found
gastroesophageal reﬂux disease and increased body mass
index to be the strongest risk factors.11,42 These are also
well-known risk factors for Barrett esophagus (BE),42 and
the majority of esophageal adenocarcinomas arises in a
background of BE.7
Multiple molecular pathways are involved in the
development of adenocarcinoma of the esophagus, includ-
ing derangements in tumor suppressor genes such as p53
and p16. In addition, deregulated activity of protoonco-
genes, regulatory genes that control proliferation through
such mechanisms as inhibition of apoptosis, also contributes
to the development of carcinoma of the esophagus [eg, EGF,
EGFR, TGF, c-erbB2 (HER2/neu), src, c-myc,a n dBRAF].
A stepwise accumulation of molecular alterations leads
to progression from metaplasia to dysplasia to adenocarci-
noma. Mitotic and apoptotic checkpoint genes (eg, cyclins,
BCL-2, and Fas/Fas ligand) may also be defective in
esophageal carcinoma. Furthermore, it is thought that
esophageal adenocarcinomas possess disruptions of cell-cell
adhesion molecules and their ligands (such as E-cadherin
and b-catenin and cathepsin B and CD44).12,19
Microsatellite instability (MSI) caused by defective
mismatch repair (MMR) is another mechanism that has
been shown in the pathogenesis of esophageal carcinoma,
particularly esophageal adenocarcinoma. In normal cells,
MMR genes correct errors in DNA sequence that arise
primarily during DNA replication. Inactivation of both
alleles of the recessive repair genes leads to defect-
ive DNA repair and a genome-wide accumulation of Copyright r 2011 by Lippincott Williams & Wilkins
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genes and protooncogenes. Tandem repeat sequences
(microsatellites) are susceptible to DNA mismatches, and
MSI is a key feature of MMR defects.12,19 Several studies
of MSI in esophageal carcinomas have been carried out,
and most of these indicate that high-level MSI (MSI-H)
status has a low prevalence in esophageal adenocarcinoma.
The prevalence of MSI, either MSI-H or “MSI-low,” has
been reported to be approximately 5% to 10%.13,20,27,43
The frequency of MSI-H, however, has been
reported inconsistently in BE-associated adenocarcino-
ma,13,20,27,43 and little is known about the clinicopatho-
logic and molecular features and the biological behavior
of microsatellite unstable BE-associated adenocarcinoma.
Thus, the aims of this study were to further clarify the
frequency of MSI and to characterize BE-associated
adenocarcinomas with or without MSI.
MATERIALS AND METHODS
Patient Population
From a prospectively collected database at Massa-
chusetts General Hospital, a series of 272 esophagec-
tomies and esophagogastrectomies for adenocarcinoma
performed between January 2000 and May 2008 were
identiﬁed. Of those, patients treated with chemotherapy
and/or radiation therapy (n=83), photodynamic therapy
(n=2), or endoscopic mucosal resection (n=4) before
resection were excluded. Of the remaining 183 cases, 108
were epicentered in the cardia or distal esophagus and
showed intestinal metaplasia of the distal esophagus
(Barrett esophagus) in the resection specimen and/or
preoperative esophageal biopsies. Of those, 32 cases with
a tumor conﬁned to the mucosa (intramucosal adeno-
carcinoma) were excluded, and the remaining 76 cases
formed our study cohort. Institutional review board
approval was procured for testing and review of existing
pathologic specimens and for clinical chart review.
Histologic Evaluation
All cases were ﬁxed in 10% buﬀered formalin and
were embedded in paraﬃn by standard procedures.
Representative sections of tumor and adjacent mucosa
stained with hematoxylin and eosin were evaluated in
each case for the following study variables: size of tumor,
depth of invasion (pT), nodal metastases (pN), presence
of distant metastases (pM), presence of lymphovascular
invasion, large vessel (venous) invasion, perineural inva-
sion, resection margin status, histologic grade (pG) and
histomorphologic features of tumor, and the background
mucosa. The American Joint Committee on Cancer
Staging Manual, 7th edition,3 was used to deﬁne and
categorize TNM cancer stage and histologic grade. The
histomorphology of tumors was classiﬁed as adenosqua-
mous carcinoma, conventional adenocarcinoma (papillary
and/or glandular), medullary carcinoma [solid growth with
tumor-inﬁltrating lymphocytes (TILs)], mucinous carcino-
ma, or signet ring cell carcinoma. Medullary, mucinous,
and signet ring cell carcinomas were deﬁned as carcinomas
with >50% of the relevant histology.
Tissue Microarray Construction
In each case, 2 to 5 tissue cores that represented
each histologic subtype were harvested from the original
paraﬃn blocks, and a total of six 2-mm-core tissue
microarray (TMA) blocks were constructed. Each TMA
block also included normal gastric body/fundic mucosa,
cardiac-type mucosa, and Barrett mucosa as controls and
5 cores of nongastroesophageal junction cancers.
Immunohistochemical Analysis
Immunohistochemical studies were carried out on
TMA 5mm sections using Ventana Benchmark (Ventana
Medical Systems, Tucson, AZ) or Dako AutostainerPlus
automated stainers (Dako Corporation, Santa Barbara,
CA). Monoclonal antibodies against 4 MMR proteins,
namely hMLH1 [Becton Dickinson (BD) Biosciences, San
Jose, CA], hMSH2 (BD Biosciences or EMD Chemicals,
Gibbstown, NJ), hMSH6 (BD Biosciences), and hPMS2
(BD Biosciences), were applied. Protein expression was
collectively evaluated in all of the tumor cells seen in
multiple cores from each case. Complete negative expres-
sion in any of the MMR proteins, with adjacent normal
mucosa or stromal/lymphoid cells exhibiting intact
nuclear staining, was considered to be positive for loss
of MMR proteins. Cases determined to potentially have
loss of MMR proteins on the TMA were conﬁrmed by
staining whole sections of tumor with immunohistochem-
istry for all 4 MMR proteins. Cases determined to have
loss of MMR proteins on whole sections were examined
by molecular microsatellite analysis.
CD3 immunostaining (Ventana) was performed to
evaluate TILs. CD3-positive T cells inﬁltrating between
tumor cells were counted in all available cores using an
Olympus BX40 microscope (total area of 40x ﬁeld equal
to 0.94mm2), and the mean CD3-positive cells/high-
power ﬁeld (HPF) was calculated in each case.
For the purpose of this study, in situ hybridization
was also performed on all available TMA sections with
an oligonucleotide probe speciﬁc for Epstein-Barr virus
(EBV)-encoded RNA (EBER) (Ventana or PNA PROBE,
Dako Corporation).
Molecular Microsatellite Analysis
Normal and tumor tissues were manually micro-
dissected from serial, 5-mm-thick unstained sections of
formalin-ﬁxed, paraﬃn-embedded tissue (3 slides; approxi-
mately 1cm2 tissue per slide). The tissue was deparaﬃnized
in xylene and rehydrated in 100% ethanol. DNA was
extracted using the Puregene DNA Puriﬁcation Kit (Gentra
Systems, Minneapolis, MN).
Polymerase chain reaction (PCR) was performed
in 20mL volumes using 1X Platinum Taq PCR buﬀer,
200mM dNTPs, 2.0mM MgCl2, 0.4mM primers, and
1.0U of Platinum Taq polymerase (all from Invitrogen,
Carlsbad, CA), with 40ng of tumor or normal DNA
as template. Primer sets consisted of the 5 reference
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Institute,4 with 50 phosphoramidite ﬂuorescent labeling
of forward primers as follows: BAT-25 (NED), BAT-26
(6–FAM), D5S346 (VIC), D17S250 (6–FAM), and
D2S123 (VIC). The primer sequences for D2S123 were
50-AACATTGCTGGAAGTTCTGG-30 (forward) and
50-GTGTCTTGACTTTCCACCTATGGGACTG-30 (re-
verse). Primer sequences for the remaining loci were
identical to those previously described23 except that a
50-GTGTCTT sequence was added to each reverse primer
to facilitate nontemplate adenylation of the 30 end of the
forward strand.
PCR was performed in a Mastercycler ep (Eppen-
dorf, Hamburg, Germany) with an initial denaturing step
at 941C for 5 minutes. This was followed by 38 cycles of
denaturing at 941C for 30 seconds, annealing at either
501Co r5 5 1C for 30 seconds, and extension at 721C for
30 seconds. The ﬁnal elongation step was at 721C for
10 minutes. PCR products were pooled and fractionated
by size using an Applied Biosystems (Foster City, CA)
3730 DNA Analyzer with GeneMapper software. Micro-
satellite loci at which tumor DNA showed a novel allele
proﬁle not present in the corresponding normal DNA
were classiﬁed as MSI unstable. MSI-H was deﬁned as 2
or more of the 5 examined microsatellite markers showing
instability, whereas MSI-low was deﬁned as only 1 marker
showing instability.
Analysis of hMLH1 Promoter Methylation
A methylation assay was performed when MMR
analysis by immunohistochemistry (IHC) was suggestive
of a loss of MLH1. The methylation status in the CpG
island 50 to the transcription start site of the hMLH1 gene
was examined by methylation-speciﬁc PCR analysis,
based on the sequence diﬀerences between methylated
and nonmethylated DNA after bisulﬁte modiﬁcation (EZ
DNA Methylation Kit; Zymo Research, Orange, CA).
Converted DNA was ampliﬁed by PCR using methyla-
tion-speciﬁc primers in a total volume of 20mL containing
2mLo f1 0   reaction buﬀer, 4.0mM MgCl2, 200mM
dNTPs, 10pmol forward and reverse primers, and 0.2mL
of Platinum Taq polymerase. Ampliﬁcation was per-
formed in an Eppendorf Mastercycler Gradient and
entailed an initial denaturation at 941C for 4 minutes
followed by 40 cycles of denaturation at 941C for 30
seconds, annealing at 621C for 30 seconds, extension at
721C for 60 seconds, and a ﬁnal extension for 10 minutes
at 721C.
Mutational Analysis of the BRAF Genes
Tumor DNA samples of MSI-high tumors were
analyzed for recurrent point mutations in BRAF codon
V600 using the single base extension SNaPshot assay
(Applied Biosystems, ABI, Foster City, CA). BRAF exon
16, which contains the target codons, was ampliﬁed in a 4-
plex PCR reaction (4mL total containing 5pmoL of
forward and reverse primers, 200mM dNTP, 2.0mM
MgCl2, 0.2U Platinum Taq Polymerase, and approxi-
mately 5 to 10ng of DNA; all reagents from Invitrogen,
Carlsbad, CA). Thermocycling conditions were as fol-
lows: 951C for 2 minutes, (941C for 15s, 581C for 30s,
721C1 5 s )  38 cycles. Unincorporated primers and
dNTPs were eliminated from the PCR reactions by
adding 2mL of an exonuclease I (Exo) and shrimp
alkaline phosphatase (SAP) mixture [USB Web, Cleve-
land, OH, 1 volume of Exo (10units/mL) to 10 volumes of
SAP (1unit/mL)], and incubating at 371C for 45 minutes
followed by 15 minutes inactivation at 801C. The
extension primer pool (approximately 14 total pmol in
1mL) mixed with RR mix (3mL, ABI) was added directly
to the cleaned up PCR ampliﬁcation product for single
base extension: 961C for 30 seconds, (961C for 10s, 501C
for 5s, 601C for 30s)  35 cycles. The extension primers
were designed to interrogate 11 bases corresponding to
the 4 target codons in either the forward or the reverse
direction (F or R): BRAF c.1798F and c.1799R. The
extension products were treated with SAP using the same
procedure as the Exo-SAP step and were then analyzed
using the ABI 3500xL Genetic Analyzer (Applied
Biosystems, Foster City, California). Detailed protocol
and primer information are available on request and will
be reported separately (Le, Iafrate, et al, unpublished
protocol).
Data Analysis
For all statistical analyses, Epi Info Version 3.5.1
(Centers for Disease Control and Prevention, Atlanta,
GA) was used. All P values were 2-sided, and statistical
signiﬁcance was set at P<0.05. For categorical data, the
w2 test was carried out, and for continuous variables, the
unpaired Student t test was applied.
RESULTS
Study Cohort
The study cases consisted of 76 BE-associated
adenocarcinomas from 66 male and 10 female patients,
with a mean age of 65.1 years (SD, 11.1y). American
Joint Committee on Cancer tumor and lymph node
stages were pT1/2/3/4=24/16/36/0 and pN0/1/2/3=37/
18/11/10, distant metastases were pM1/x=3/73, and
histology grades were pG1/2/3=4/33/39; the mean
tumor size was 4.0cm (SD, 1.9cm). Lymphovascular
invasion was noted in 40 (53%) cases, perineural invasion
in 30 (39%) cases, and venous invasion in 18 (24%) cases.
Resection margins were involved by tumor in 10 (13%)
cases. The histomorphologic types included adenosqua-
mous cell carcinoma (n=1), conventional adenocarcino-
ma (n=73), and medullary carcinoma (n=2). Of
the 73 tumors with conventional adenocarcinoma, focal
mucinous diﬀerentiation was seen in 6 cases, focal signet
ring cell features were seen in 4 cases, both mucinous
and signet ring cell components were seen in 9 cases,
and focal medullary growth was seen in 1 case. No case
was strictly classiﬁed into signet ring cell carcinoma or
mucinous carcinoma.
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Unstable BE-associated Adenocarcinoma
Of 76 BE-associated adenocarcinomas in the study,
5 (6.6%) cases showed concurrent MLH1 and PMS2
loss by IHC (Table 1). The remaining 71 cases showed
preserved nuclear expression of MLH1, PMS2, MSH2,
and MSH6. All the 5 cases with loss of MLH1 and PMS2
by IHC were conﬁrmed to have MSI-H by PCR assay
(Table 1). Representative results from MLH1 IHC and
MSI PCR are shown in Figures 1 and 2, respectively.
Selected clinicopathologic and follow-up data of the 5
patients with microsatellite unstable (MSI-H) BE-associated
adenocarcinoma are shown in Table 1. Compared with 71
patients with a MSI IHC-negative (MSI ) tumor, those
w i t haM S I - Ht u m o rw e r em o r el i k e l yt ob eo l d e r( 7 6yv s
64y, P=0.006). Although a MSI-H tumors were more
likely to be large (5.3cm vs 3.9cm, P=0.163) with
lymphatic invasion (100% vs 49%, P=0.056), the diﬀer-
ence did not reach statistical signiﬁcance, and there was no
diﬀerence in nodal status between the 2 groups (Table 2).
The histomorphology of MSI-H tumors consisted of
conventional adenocarcinoma with TILs (n=1), medul-
lary carcinoma (n=1), and adenocarcinoma with hetero-
genous histology (n=3) [with a medullary component
(n=1), with a signet ring cell component (n=1), and with
signet ring cell and mucinous components (n=1)],
recapitulating the colonic counterpart (Fig. 1), and was
in stark contrast to MSI  tumors that mostly exhibited
conventional adenocarcinoma (P=0.027)(Table2).
TILs were signiﬁcantly increased in MSI-H tumors
compared with MSI  tumors (Table 2). The average
count of CD3-positive T cells inﬁltrating within tumor
cells was 42.9/HPF (range, 21 to 95) for MSI-H tumors
and 5.2/HPF (range, 0-102) for MSI  tumors (P<
0.0001). Interestingly, in the MSI  group, a signi-
ﬁcant increase in TILs (>20 TILs/HPF) was seen in only
1 case with medullary carcinoma, which was the sole case
positive for EBER. It should be noted that no other case,
either MSI-H or MSI , exhibited EBER.
Molecular Profile of Microsatellite Unstable
BE-associated Adenocarcinoma
Of the 5 MSI-H tumors, all but 1 showed hMLH1
promoter methylation (Fig. 3), but none of the examined
cases exhibited BRAF V600E mutations.
Survival of Microsatellite Unstable
BE-associated Adenocarcinoma
Of the 4 patients with a MSI-H tumor and available
follow-up data, 1 died of sepsis during the postoperative
period, and 2 died of disease at 12 months and 23 months
after operation. The remaining patient was alive without
disease after esophagogastrectomy for T2N0 adenocarci-
noma and no adjuvant therapy (Table 1). There was no
statistical diﬀerence in overall survival between patients with
a MSI-H BE-associated adenocarcinoma and those with a
MSI  tumor (median survival: 23mo vs 32mo, P=0.285).
DISCUSSION
MSI-H has been reported hMLH1 in approximately
15% of colorectal, gastric, and endometrial cancers and
in lower frequencies in a minority of other tumors.45
Several studies have collectively reported that defective
MMR occurs in a small subset; 4.7% (13 of 274) of BE-
associated adenocarcinomas.12,13,19,20 In this study, we
not only conﬁrmed MSI-H in an appreciable minority,
6.6% of invasive adenocarcinomas arising in the back-
ground of BE, but also showed their association with
unique clinicopathologic features.
Among the prototype and most extensively studied
tumors, that is MSI-H colorectal cancers, the vast majority
is associated with sporadic methylation of the hMLH1
promoter. However, germline mutations in MMR genes
also predispose to MSI-H colorectal cancers in patients with
hereditary nonpolyposis colorectal cancer (HNPCC).14,22,39
It has been well documented that MSI-H colorectal cancers,
both sporadic and syndromic, have a better overall pro-
gnosis compared with microsatellite stable colorectal
cancers.39 Growing evidence suggests that patients with
TABLE 1. Characteristics of Microsatellite Unstable BE-associated Adenocarcinomas
Case
Age
(y) Sex
Personal
History of
Cancer
Family
History of
Cancer
Tumor
Size (cm) pT pN Histology
TIL
(/HPF) MLH1*
F/U
(mo)w Status
1 78 M None None 5.5 3 1 Adenocarcinoma with
mucinous and signet ring cell
components
21 Positive 22.7 DOD
2 75 M None Breast cancer
(mother)
7.5 3 1 Medullary carcinoma 95 Negative 0.5 DOC
3 67 M None None 2.8 2 0 Adenocarcinoma with a signet
ring cell component
23 Positive 11.7 DOD
4 78 F Rectal cancer
(age 78y)
Rectal cancer
(mother)
6.0 3 0 Adenocarcinoma with a
medullary component
42 Positive 3.1 Lost
5 83 F None None 4.5 2 0 Conventional adenocarcinoma
with tumor-inﬁltrating
lymphocytes
33 Positive 21.7 AWOD
*hMLH1 promoter methylation.
wFollow-up.
AWOD indicates alive without disease; DOC, dead of complication; DOD, dead of disease; F, female; Lost, lost to follow-up; M, male.
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chemotherapy with ﬂuorouracil (5–FU), which has been
commonly used for the treatment of both colorectal cancer
and esophageal adenocarcinoma.36,37 On account of these
clinical diﬀerences and the magnitude of importance in
recognizing patients with HNPCC, both clinicians and
FIGURE 1. Microsatellite unstable BE-associated adenocarcinomas with a heterogenous morphology. A, Medullary carcinoma showing
a pushing border (magnification,  100). B, Adenocarcinoma with signet ring cell and mucinous components (magnification,  400).
C and D, Medullary carcinoma with abundant lymphocytes infiltrating a solid growth of carcinoma cells (magnification,  400. C:
Hematoxylin and Eosin stain, D: CD3 stain). E and F, Conventional adenocarcinoma with tumor infiltrating lymphocytes (TILs). MLH1
immunostain (F) highlights nuclei of stromal cells and TILs, but those of the tumor cells are devoid of staining (magnification,  400).
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r 2011 Lippincott Williams & Wilkins www.ajsp.com | 651FIGURE 2. Results of MSI analysis for representative loci from case 2. Electropherograms of labeled PCR products of paired tumor
(T) and normal (N) DNA are shown for BAT25, a mononucleotide repeat (A) and for D17S250, a dinucleotide repeat (B). PCR
product fragment size is represented on the x axis and fluorescence units are represented on the y axis. A single allele is observed
at BAT25. Two alleles are observed at D17S250; arrows indicate the individual alleles. For both microsatellite repeats, the tumor
DNA shows a novel allele profile that differs from the corresponding allele profile amplified from normal DNA.
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of colorectal cancers that correlate with MSI.
Numerous studies have linked MMR deﬁciency in
colorectal cancer to certain morphologic character-
istics, such as poor tumor diﬀerentiation, medullary type,
mucinous type, signet ring cell component, histologic
heterogeneity, and increased TILs.17,25,38 Recognizing these
features may guide pathologists and clinicians in deciding
which cases to evaluate for MSI.25 With regard to the
histologic features of BE-associated invasive carcinomas, as
shown in this study, the majority exhibit the histology of
moderately or well-diﬀerentiated conventional adenocarci-
noma. Poorly diﬀerentiated carcinomas composed of sheets
of epithelial cells with ill-formed glandular lumina, signet
ring cell features, and mucinous (colloid) diﬀerentiation are
uncommon, comprising 5% to 10% of cases.26,29 Similarly,
there are few cases of medullary26,34 or lymphoepithe-
lial18,30 carcinoma of the esophagus in the literature, and to
our knowledge, only a single case of BE-associated
adenocarcinoma with lymphoid stroma (medullary carci-
noma) has been reported so far.35 Conversely, in this study,
4 of the 5 MSI-H tumors exhibited poor tumor diﬀerentia-
tion, including medullary morphology, and the remaining
case showed moderately diﬀerentiated adenocarcinoma
with increased TILs. The histologic heterogeneity was also
characteristic of microsatellite unstable BE-associated
adenocarcinomas, similar to the colonic counterpart.
Of the various histologic features, the medullary
morphology seems to be associated with distinct mechan-
isms of pathogenesis. In our cohort, we used the term
“medullary” to refer to a poorly diﬀerentiated carcinoma
with syncytial islands or complex collections of malignant
cells exhibiting prominent inﬁltration by intraepithe-
lial lymphocytes. It is noted that one can diagnose a
“lymphoepithelioma-like” carcinoma when someone con-
fronts an EBV+ medullary carcinoma, particularly in other
parts of the body,10,16,44 and we recognize that our deﬁnition
of medullary carcinoma overlaps somewhat with
“lymphoepithelioma-like” carcinoma in this sense. Using a
similar deﬁnition, MSI-H status has been reported in 90%
to 100% of medullary carcinomas of the colon,1,21,32 which
comprise only 4% of colorectal cancers.14 In the stomach,
medullary carcinomas have been observed in association
with not only MSI, but also EBV infection. EBER positivity
has been identiﬁed in 37.5% to 100% of gastric medullary
carcinomas, especially in the postgastrectomy sto-
mach.5,6,8,40 Similarly, MSI-H was much more frequently
seen in medullary carcinomas of the stomach than
nonmedullary cancers (41.2% vs 1.6%).24 In the esophagus
and esophagogastric junction, Wu et al46 reported the
association of MSI and medullary carcinoma. They found 3
(60%) of 5 tumors with MSI-H exhibiting features of
medullary carcinoma with lymphoid inﬁltrate in their cohort
of 92 cases. The cohort, however, included both BE-
associated and non-BE tumors, and the authors did not
clearly specify the presence or absence of the BE background
in those 3 cases. In our study consisting solely of BE-
associated adenocarcinomas, 2 (67%) of the 3 tumors with a
medullary carcinoma component showed MSI-H. Interest-
ingly, the remaining one case was positive for EBER.
The presence of MSI raises the possibility of
HNPCC, as carcinomas arising in the setting of germline
mutation in MMR genes, particularly hMSH1 and
hMSH2, usually exhibit MSI-H.33,39 In fact, 1 microsatellite
unstable BE-associated adenocarcinoma with loss of
MSH2 protein expression in a patient with a family history
of multiple cancers suggestive of HNPCC, has been
reported.13 Among patients who do not manifest HNPCC
(sporadic cases), MSI-H is often the consequence of
promoter methylation (and subsequent silencing) of
hMLH1,41 and is often associated with BRAF mutation.
Conversely, HNPCC seldom exhibits the CpG island
methylator phenotype or BRAF mutation.28 In this study,
all 5 cases with MSI-H tumor showed loss of MLH1
expression with preserved MSH2 nuclear expression in
tumor cells and hMLH1 promoter methylation was found
in 4 cases, whereas none showed BRAF mutations.
Although the possibility of concurrent germline mutation
and promoter methylation of hMLH1 cannot be excluded,9
TABLE 2. Clinicopathologic Features of MSI-H and MSI 
Barrett Esophagus-Associated Adenocarcinomas
MSI-H
(n=5)
MSI 
(n=71) Pz
Age (y) 76.2±5.9 64.4+11.0 0.0060
Sex (male %) 60 89
Location
Distal esophagus 2 (40%) 32 (45%)
Esophagogastric junction 3 (60%) 39 (55%)
Tumor size (cm) 5.3±1.8 3.9±1.8
pT (Tumor)
1 0 24 (34%)
2 2 (40%) 14 (20%)
3 3 (60%) 33 (46%)
pN (Node)
0 3 (60%) 34 (48%)
1 2 (40%) 16 (23%)
2 0 11 (15%)
3 0 10 (14%)
pM (Metastasis)
1 0 3 (4.2%)
X 5 (100%) 68 (96%)
pG (Grade)
1 0 4 (5.6%)
2 1 (20%) 32 (45%)
3 4 (80%) 35 (49%)
Lymphovascular invasion
(positive %)
100 49 0.056
Perineural invasion (positive%) 40 39
Venous invasion (positive %) 20 24
Margin status (positive%) 0 14
Histology 0.027y
Adenosquamous carcinoma 0 1 (1.4%)
Conventional adenocarcinoma* 1 (20%) 52 (73%)
with medullary carcinomaw 2 (40%) 1 (1.4%)
with signet ring cell carcinoma 1 (20%) 3 (4.2%)
with mucinous carcinoma 0 6 (8.4%)
with mucinous and signet ring cell 1 (20%) 8 (11%)
Tumor inﬁltrating lymphocytes 42.9±0.3 5.2±13.0 <0.0001
*Conventional adenocarcinoma without additional component(s).
wIncluding 2 tumors solely composed of medullary carcinoma.
zOnly P values <0.100 are listed.
yConventional adenocarcinoma vs the others.
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signiﬁcant family or personal history suggesting HNPCC,
these 5 MSI-H tumors most likely represent sporadic MSI-
H tumors.38 The etiology of MLH1 protein expression loss
associated with MSI-H is yet to be determined in the
remaining one case; however, given the clinical proﬁle
(Table 1), the possibility of HNPCC may be less likely.
The survival advantages (and lower tumor stage)
associated with MSI-H that have been reported in the
colonic counterpart39 and in the esophagus46 were not
conﬁrmed in this study. There was a trend toward the
microsatellite unstable BE-associated adenocarcinomas
presenting with a larger tumor and at a more advanced
stage than those with preserved MMR protein expression,
although there was no diﬀerence in outcomes between the
2 groups. BE-associated adenocarcinomas are generally
found at a less advanced stage than non-Barrett adeno-
carcinomas; this is most likely due to surveillance proto-
cols for BE and/or reﬂux symptoms.31 Thus, the results of
this study may indicate diﬀerences in biology between
microsatellite unstable and microsatellite stable tumors in
the background of BE. However, further larger-scale
studies are warranted to clarify survival in patients with a
MSH-H BE-associated adenocarcinoma.
One of the limitations of our study is that we did not
conduct MSI PCR testing in tumors with preserved MMR
protein expression. Although we cannot exclude the possibi-
lity that such cases might harbor a mutant MMR gene that
yields a nontruncated protein, which retains the epitope
recognized by IHC, given the high correlation between MSI
IHC and PCR,15 it is less likely that those cases with
preserved protein expression would show an MSI-H proﬁle
by PCR.
In conclusion, MSI-H is rare in BE-associated
adenocarcinomas (6.6% in this series) but is associated
with clinicopathologic features fairly similar to sporadic
microsatellite unstable colorectal cancers. Given the grow-
ing evidence that indicates lack of beneﬁts from adjuvant
therapy with 5-FU in the colonic counterpart, it may be
important to identify MSI-H in BE-associated adeno-
carcinomas, as they are commonly treated with similar
chemotherapeutic agents. The results of this study suggest
medullary morphology, histologic heterogeneity, and/or
increased TILs to be clues to MSI in not only colorectal
cancers but also in BE-associated adenocarcinomas. On
account of its scarcity, the survival impact of MSI in BE-
associated adenocarcinomas still needs to be more clearly
deﬁned in larger scale studies.
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